Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting267%
active_not_recruiting133%

Recent Activity

3 active trials
Showing 3 of 3
active_not_recruitingnot_applicable

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

NCT05860595
recruitingnot_applicable

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

NCT06219239
recruitingphase_1

Β-Thalassemia Treatment with KL003 Cell Injection

NCT06280378

Clinical Trials (3)

Showing 3 of 3 trials
NCT05860595Not Applicable

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Active Not Recruiting
NCT06219239Not Applicable

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

Recruiting
NCT06280378Phase 1

Β-Thalassemia Treatment with KL003 Cell Injection

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
3